Clinical trials

Phase I

An Open Label, First in Human (FIH), Phase 1a/1b Trial of LVGN7409 (CD40 Agonist Antibody) as a Single Agent, in Combination With LVGN3616 (Anti-PD-1 Antibody), and in Combination With LVGN3616 and LVGN6051 (CD137 Agonist Antibody) in Patients With Locally Advanced, Relapsed, Refractory, or Metastatic Malignancy

NCT04635995

VIEW TRIAL

An Open Label, Phase I Trial of LVGN7409 as Single Agent in Locally Advanced, Metastatic or Recurrent/Refractory Malignancy

NCT05152212

VIEW TRIAL

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT05075993

VIEW TRIAL

More about LVGN7409

CD40 is a costimulatory protein found on antigen-presenting cells (APCs) and is required for their activation. The binding of CD154 (CD40L) on T cells to CD40 activates antigen presenting cells and induces a variety of downstream effects.
Similar to the endogenous CD40 ligand (CD40L or CD154), CD40 agonistic antibody LVGN7409 binds to CD40 on a variety of immune cell types. This triggers the cellular proliferation and activation of antigen-presenting cells (APCs), and activates B-cells, and effector and memory T-cells. This results in an enhanced immune response against tumor cells. Evidence to date suggests that CD40 activation is a critical and nonredundant mechanism to convert so-called cold tumors to hot ones (with prominent tumor infiltration of T cells), sensitizing them to checkpoint inhibition.
Based on different expression profile and anti-tumor activity mechanism between CD40 and other T-cell activating drugs, anti-CD40 antibody is an excellent candidate for combination therapy with anti-PD-1, anti-PD-L1 or anti-CTLA4 antibodies etc.
For more scientific rationale, please visit Cancer Immunotherapy and xLink MAb.

Our Progress

We are conducting Phase I trials of LVGN7409 as monotherapy and in combination with PD-1 antibodies in the USA and China, in adult patients with advanced malignancies.
If you as a patient or caregiver wish to participate in this study, please contact us at the following address: clinical@lyvgen.com or send us a message